Tag : NEOADJUVANT CHEMORADIOTHERAPY

CONFERENCE UPDATE

Improved outcomes with FLOT perioperative chemotherapy vs. CROSS neoadjuvant chemoradiation for esophageal cancer: The ESOPEC Trial
The incidence of esophageal adenocarcinoma (EAC) is increasing, particularly in high-income countries, with almost 86,000 new cases globally in 2020. While surgery is the mainstay for cure in non-metastatic disease, multimodality treatment can improve survival in these patients.